Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1
- Registration Number
- NCT00597909
- Locations
- 🇺🇸
Permian Research Foundation, Odessa, Texas, United States
🇺🇸UCSF-Fresno University, Fresno, California, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT00563316
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 167
- Registration Number
- NCT00530114
Denosumab Adherence Preference Satisfaction Study
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 250
- Registration Number
- NCT00518531
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT00515203
Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 40
- Registration Number
- NCT00503490
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 658
- Registration Number
- NCT00460265
Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 906
- Registration Number
- NCT00450216
Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 627
- Registration Number
- NCT00450658
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 71
- Registration Number
- NCT00431496
© Copyright 2024. All Rights Reserved by MedPath